{
    "2018-06-20": [
        [
            {
                "time": "2023-10-01",
                "original_text": "Experimental New Drugs That Could Be Worth $47 Billion",
                "features": {
                    "keywords": [
                        "experimental drugs",
                        "worth",
                        "billion"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "dividend stocks",
                        "better"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "finance"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}